Tech Company Financing Transactions
Nouscom Funding Round
M Ventures, Revelation Partners and 5AM Ventures participated in a $135 million Series D venture round for Nouscom. The round was announced on 10/19/2026.
Transaction Overview
Company Name
Announced On
10/19/2026
Transaction Type
Venture Equity
Amount
$135,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead asset, NOUS-209, through a global, registration-enabling clinical trial for cancer interception in Lynch Syndrome (LS) carriers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Bäumleingasse 18
Basel, 4051
CH
Basel, 4051
CH
Phone
Website
Email Address
Overview
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experiencedenterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marina Udier
Chief Operating Officer
Richard Davis
Chief Scientific Officer
Elisa Scarselli
Chief Technical Officer
Stefano Colloca
Browse more venture capital transactions:
Prev: 10/19/2026: RapidCanvas venture capital transaction
Next: 10/19/2026: Huppa venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs